Xeris names CEO John Shannon board chair, effective July 1, 2026

XERIS PHARMACEUTICALS INC

XERIS PHARMACEUTICALS INC

XERS

0.00
  • Xeris Biopharma named CEO John Shannon chair of the board, effective July 1, 2026.
  • Marla Persky stepped down as chair, remaining on the board as lead independent director from July 1, 2026.
  • Nerissa Kreher joined the board on July 1, 2026, expanding it to eight members.
  • Kreher is chief medical officer at Alltrna; previously held CMO roles at Entrada Therapeutics, Tiburio Therapeutics, AVROBIO.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260630562464) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.